Cyklokapron 250 mg, 500 mg

Cyklokapron is a medication primarily used to manage bleeding disorders by promoting blood clotting. It contains the active ingredient tranexamic acid, which works by inhibiting the breakdown of fibrin, a crucial protein involved in blood clot formation. This action helps to reduce excessive bleeding in various medical situations, such as heavy menstrual bleeding, surgical procedures, or trauma.

The bleedings or risk of bleedings on a background of strengthening of fibrinolysis (malignant new growths of pancreas and prostate glands, operations on organs of a thorax, postnatal bleedings, manual removal of afterbirth, leucosis, diseases of the liver, previous therapy by streptokinase – cases of generalized fibrinolysis; uterus, nasal, gastroenteric bleedings, hematuria, bleedings after prostatectomy, conization of the cervix in the occasion of carcinoma, extraction of a tooth at patients with hemorrhagic diathesis – cases of local fibrinolysis).

Hereditary angioedema, allergic diseases (eczema, allergic dermatitis, nettle-rash, a medicinal and toxic rash), inflammatory diseases (tonsillitis, pharyngitis, laryngitis, stomatitis, aphthae of the mucous membrane of an oral cavity).

Collateral action

• From the dermatological system: Rash, Skin itch (pruritus) , Raised sensitivity to stimuli.
• From the digestive system: Decrease in appetite, Nausea, Diarrhea, Heartburn.
• From CNS: Drowsiness.
• From the organ of sight: Infringement of color sight (color vision deficiency).

Contra-indications

• From the nervous system: increased sensitivity to the medication.
• From the cardiovascular system: careful use in patients with thrombohemorrhagic complications, thrombosis (including cerebral thrombosis, myocardial infarction, and thrombophlebitis), or those at risk of these conditions.
• Other: caution is advised when combined with heparin and indirect anticoagulants.

Special instructions

At renal insufficiency (depending on a degree of increase of creatinine of serum) reduce a dose and frequency rate of introduction. During and after treatment within several days supervision of the ophthalmologist with a check of acuteness, fields, and color sight, a survey of an eye bottom is necessary.

With care apply in a combination with fabric hemostatic preparations, hemocoagulase (in greater doses), heparin. At treatment of hematuria of renal genesis the risk of mechanical anger as a result of the formation of a clot in the urethra increases.